The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Gene Therapy For Parkinson’s Disease Market From 2026 To 2030?
The gene therapy for parkinson’s disease market size has experienced rapid expansion over recent years. This market is projected to expand from $0.64 billion in 2025 to reach $0.81 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 26.3%. Historically, this growth has been driven by several factors, including developments in viral vector engineering, a deeper comprehension of Parkinson’s disease pathology, increased financial support for neuroscience research, the introduction of enhanced delivery technologies, and promising outcomes from initial clinical trials.
The gene therapy for Parkinson’s disease market size is projected for substantial expansion in the coming years. It is set to reach $2.05 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.0%. This anticipated growth stems from escalating investments in therapies for neurodegenerative conditions, increased adoption of personalized gene therapy methods, the expansion of clinical pipelines in their late stages, a rising need for disease-modifying treatments, and advancements in minimally invasive delivery technologies. Prominent trends throughout this period involve the accelerated development of viral vector-based therapies, a sharpened focus on strategies to restore dopamine, wider application of neurotrophic factor gene delivery, the broadening of precision intracerebral delivery techniques, and a greater emphasis on sustained therapeutic efficacy.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp
What Major Drivers Are Influencing Demand In The Gene Therapy For Parkinson’s Disease Market?
The increasing focus on personalized medicine is anticipated to drive the expansion of the gene therapy for Parkinson’s disease market in the future. Personalized medicine is defined as a medical strategy that customizes treatment and prevention plans based on an individual’s unique genetic profile, lifestyle choices, and environmental factors. The appeal of personalized medicine is increasing, driven by a rising need for focused treatments that enhance efficacy and reduce undesirable side effects. In the context of personalized medicine, gene therapy for Parkinson’s disease is utilized to provide customized genetic alterations aimed at restoring dopamine function and targeting specific disease mechanisms unique to each patient. For example, the Personalized Medicine Coalition, a US-based non-profit, stated in February 2024 that the US Food and Drug Administration (FDA) approved 16 novel personalized treatments for patients with rare diseases in 2023, which represents a significant rise from the 6 approvals recorded in 2022. Consequently, the expanding interest in personalized medicine is fueling the growth of the gene therapy for Parkinson’s disease market.
Which Segments Are Included In The Analysis Of The Gene Therapy For Parkinson’s Disease Market?
The gene therapy for parkinson’s disease market covered in this report is segmented –
1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy
2) By Vector Type: Viral Vectors, Non-Viral Vectors
3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes
4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors
2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy
Which Trends Are Impacting The Growth Of The Gene Therapy For Parkinson’s Disease Market?
Leading companies in the gene therapy for Parkinson’s disease market are concentrating on creating advanced treatments like regenerative medicine advanced therapy. Their aim is to improve neuronal survival, bring back dopamine function, and offer enduring disease-modifying advantages for individuals with Parkinson’s disease. Regenerative medicine advanced therapy (RMAT) denotes a particular designation from the United States Food and Drug Administration (FDA). This designation is given to regenerative medicine items, including cell therapies, gene therapies, and tissue-engineered products, which are designed to address, alter, reverse, or cure critical or life-threatening conditions. For example, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy firm, launched AB-1005. This investigational AAV2-GDNF gene therapy obtained the FDA regenerative medicine advanced therapy (RMAT) designation. This designation, aimed at accelerating the development and assessment of promising treatments, was awarded following data submission by AskBio. This included clinical evidence from its Phase Ib open-label, uncontrolled trial, which showcased AB-1005’s capability to decelerate disease progression and enhance motor function in Parkinson’s patients.
Which Key Industry Participants Are Active In The Gene Therapy For Parkinson’s Disease Market?
Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.
Read the full gene therapy for parkinson’s disease market report here:
Which Region Shows The Strongest Potential For Future Growth In The Gene Therapy For Parkinson’s Disease Market?
North America was the largest region in the gene therapy for parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Gene Therapy For Parkinson’s Disease Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28231&type=smp
Browse Through More Reports Similar to the Global Gene Therapy For Parkinson’s Disease Market 2026, By The Business Research Company
Genes Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Anti Parkinson Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report
Nucleic Acid Based Gene Therapy Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model